Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies-Reference-Cited by-同舟云学术

Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies

Published:2024-05-08 Issue:5 Volume:150 Page:
ISSN:1432-1335
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Wang Kang,Wang Yun,Yin Kai

Abstract

AbstractColitis-associated colorectal cancer has been a hot topic in public health issues worldwide. Numerous studies have demonstrated the significance of myeloid-derived suppressor cells (MDSCs) in the progression of this ailment, but the specific mechanism of their role in the transformation of inflammation to cancer is unclear, and potential therapies targeting MDSC are also unclear. This paper outlines the possible involvement of MDSC to the development of colitis-associated colorectal cancer. It also explores the immune and other relevant roles played by MDSC, and collates relevant targeted therapies against MDSC. In addition, current targeted therapies for colorectal cancer are analyzed and summarized.

Funder

the Research Project of the Jiangsu Commission of Health

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00432-024-05755-w.pdf

Reference112 articles.

1. Akdeniz N, Kaplan MA, Uncu D, İnanç M, Kaya S, Dane F, Işıkdoğan A (2021) The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. Int J Colorectal Dis 36(6):1311–1319. https://doi.org/10.1007/s00384-021-03888-9

2. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Diaz LA Jr (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383(23):2207–2218. https://doi.org/10.1056/NEJMoa2017699

3. André T, Falcone A, Shparyk Y, Moiseenko F, Polo-Marques E, Csöszi T, Saunders MP (2023) Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol 8(2):133–144. https://doi.org/10.1016/s2468-1253(22)00334-x

4. Bitsch R, Kurzay A, Özbay Kurt F, De La Torre C, Lasser S, Lepper A, Umansky V (2022) STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. J Immunother Cancer 10(3):e004384. https://doi.org/10.1136/jitc-2021-004384

5. Boige V, Blons H, François E, Ben Abdelghani M, Phelip JM, Le Brun-Ly V, Bouché O (2023) Maintenance therapy with cetuximab after FOLFIRI plus cetuximab for ras wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Netw Open 6(9):e2333533. https://doi.org/10.1001/jamanetworkopen.2023.33533